Amphastar Pharmaceuticals (AMPH) Finished Goods (2015 - 2026)

Amphastar Pharmaceuticals' Finished Goods history runs 12 years deep, the most recent figure standing at $22.9 million for Q1 2026.

• In Q1 2026, Finished Goods fell 40.46% year-over-year to $22.9 million; the TTM figure through Mar 2026 stood at $22.9 million (down 40.46% YoY), while the FY2025 annual figure was $29.6 million, down 24.87% from the prior year.
• Finished Goods was $22.9 million for Q1 2026 at Amphastar Pharmaceuticals, down from $29.6 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $41.6 million in Q2 2025 to a low of $14.5 million in Q1 2022.
• Historically, Finished Goods has averaged $27.8 million across 5 years, with a median of $27.4 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Finished Goods jumped 91.35% in 2023, then tumbled 40.46% in 2026.
• A 5-year view of Finished Goods shows it stood at $18.9 million in 2022, then jumped by 31.99% to $24.9 million in 2023, then surged by 58.14% to $39.4 million in 2024, then slipped by 24.87% to $29.6 million in 2025, then decreased by 22.71% to $22.9 million in 2026.
• The last three Finished Goods figures came in at $22.9 million (Q1 2026), $29.6 million (Q4 2025), and $37.7 million (Q3 2025), per Business Quant data.